IDORSIA AG SF-,05
2,33€
+0,33 (+16,52%)
01.12.2023, 22:59:58 Uhr
WKN: A2DTEB ISIN: CH0363463438 Wertpapiertyp: Aktie Währung: Euro
- 1T
- 1W
- 1M
- 3M
- 6M
- 1J
- 3J
- 5J
- 10J
- Max
Weltmärkte
- DAX ® +182,09 +1,12% 16.397,52
- MDAX ® +309,07 +1,18% 26.492,49
- TecDAX ® +12,46 +0,39% 3.209,04
- E-STOXX 50 ® +36,04 +0,82% 4.418,51
- NASDAQ 100 +49,71 +0,31% 15.997,58
- NIKKEI -45,05 -0,13% 33.477,59
- HANG SENG -187,05 -1,10% 16.830,30
Kursperformance
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Tag | -- | -- |
| 1 Woche | 1,70€ | +37,35% |
| 1 Monat | 1,80€ | +29,33% |
| 6 Monate | 8,09€ | -71,24% |
| Lfd. Jahr (YTD) | 14,00€ | -83,37% |
| 1 Jahr | 14,39€ | -83,82% |
| 3 Jahre | 25,30€ | -90,80% |
| 5 Jahre | 16,94€ | -86,26% |
Kursdaten
| Kurs | 2,33€ |
| Eröffnung | 2,08€ |
| Geld | 2,27€ |
| Brief | 2,33€ |
| Tages-Hoch | 2,40€ |
| Tages-Tief | 2,08€ |
| 52 Wochen-Hoch | 17,83€ |
| 52 Wochen-Tief | 1,56€ |
| Allzeit-Hoch | 31,65€ |
| Allzeit-Tief | 1,56€ |
Nachrichten
- GlobeNewswire: New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023 - 03.11.2023, 22:30:00 Uhr
- GlobeNewswire: Idorsia gibt Finanzergebnisse für die ersten neun Monate 2023 bekannt – Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert - 24.10.2023, 07:00:00 Uhr
- GlobeNewswire: Idorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023 - 23.10.2023, 07:00:00 Uhr
- GlobeNewswire: Invitation to Idorsia's Nine-Month 2023 Financial Reporting webcast and conference call - 17.10.2023, 17:45:00 Uhr
- GlobeNewswire: Idorsia reacquires the world-wide rights to aprocitentan - 06.09.2023, 07:00:00 Uhr
- GlobeNewswire: Idorsia kündigt eine Kostensenkungsinitiative an, die bis Ende 2023 umgesetzt werden soll - 21.07.2023, 07:00:00 Uhr
- GlobeNewswire: Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million - 20.07.2023, 08:30:00 Uhr
- GlobeNewswire: Invitation to Idorsia's HY 2023 Financial Results webcast and conference call - 18.07.2023, 17:45:00 Uhr
- GlobeNewswire: Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS - 10.07.2023, 07:00:00 Uhr
- GlobeNewswire: New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023 - 26.06.2023, 17:45:00 Uhr
